This extraordinary case illustrates a rare convergence of two overlapping hereditary cancer syndromes – Li-Fraumeni syndrome (LFS) and hereditary breast and ovarian cancer (HBOC), driven by germline mutations in TP53 and BRCA1 , respectively, and manifesting as five distinct malignancies across the lifetime of a single patient. Hereditary cancer syndromes are often defined by singular germline mutations; however, the coexistence of multiple pathogenic variants in tumour suppressor genes may profoundly alter the phenotypic landscape. The functional intersecting overlap of these genes – governing genome stability, DNA repair and cell cycle regulation – forms a core tumour suppressor network. Disruption across co-existing germline mutations creates a uniquely permissive environment for tumorigenesis. The clinical implications of such multigenic inheritance are poorly understood due to their rarity. We report a case of a female patient with dual germline TP53 and BRCA1 , and subsequently, development of new somatic profiling revealed additional oncogenic events as second hit BRAF V600E, RB1, FGFR3 and IDH2 mutations who developed a constellation of malignancies over time. This report aims to dissect the molecular chronology, explore mechanistic synergies and highlight implications for targeted therapy, surveillance and counselling.
No takes yet. Share an insight, caveat, or question.
Ranjan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: